- Home
- Publications
- Publication Search
- Publication Details
Title
Predicting immunotherapy response through genomics
Authors
Keywords
-
Journal
CURRENT OPINION IN GENETICS & DEVELOPMENT
Volume 66, Issue -, Pages 1-9
Publisher
Elsevier BV
Online
2020-12-08
DOI
10.1016/j.gde.2020.11.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumor mutational burden and PTEN alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer
- (2020) Romualdo Barroso-Sousa et al. CLINICAL CANCER RESEARCH
- Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies
- (2020) Richard K. Yang et al. Oncotarget
- Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
- (2020) Jean-David Fumet et al. EUROPEAN JOURNAL OF CANCER
- A novel NGS-based microsatellite instability (MSI) status classifier with 9 loci for colorectal cancer patients
- (2020) Kai Zheng et al. Journal of Translational Medicine
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
- (2020) David A. Braun et al. NATURE MEDICINE
- The SWI/SNF complex in cancer — biology, biomarkers and therapy
- (2020) Priya Mittal et al. Nature Reviews Clinical Oncology
- Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability‐High End‐Stage Cancers and Poor Performance Status Related to High Disease Burden
- (2020) Filippo Pietrantonio et al. ONCOLOGIST
- MHC-I genotype and tumor mutational burden predict response to immunotherapy
- (2020) Aaron M. Goodman et al. Genome Medicine
- Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers
- (2020) Fausto Petrelli et al. JAMA Oncology
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
- (2020) Naiyer A. Rizvi et al. JAMA Oncology
- Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
- (2020) Jessica Roelands et al. Journal for ImmunoTherapy of Cancer
- Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
- (2020) Diana M Merino et al. Journal for ImmunoTherapy of Cancer
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
- (2019) Zhijie Wang et al. JAMA Oncology
- Genomic correlates of response to immune checkpoint blockade
- (2019) Tanya E. Keenan et al. NATURE MEDICINE
- Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response
- (2019) Rajarsi Mandal et al. SCIENCE
- Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
- (2019) Sandra Assoun et al. LUNG CANCER
- ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer
- (2019) Lin Li et al. Cells
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma
- (2019) David A. Braun et al. JAMA Oncology
- Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
- (2019) Hong Sook Kim et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
- (2019) Diego Chowell et al. NATURE MEDICINE
- Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2019) David Liu et al. NATURE MEDICINE
- TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma
- (2018) Jerome Biton et al. CLINICAL CANCER RESEARCH
- A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
- (2018) Deng Pan et al. SCIENCE
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
- (2018) Diana Miao et al. SCIENCE
- Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers
- (2018) Daniel J. McGrail et al. Nature Communications
- Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
- (2018) Michäel Duruisseaux et al. Lancet Respiratory Medicine
- Cancer immunoediting and resistance to T cell-based immunotherapy
- (2018) Jake S. O’Donnell et al. Nature Reviews Clinical Oncology
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth
- (2017) Giovanni Germano et al. NATURE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
- (2017) Teresa Davoli et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
- (2016) Leandro M. Colli et al. CANCER RESEARCH
- Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
- (2016) Nadeem Riaz et al. NATURE GENETICS
- Classification and characterization of microsatellite instability across 18 cancer types
- (2016) Ronald J Hause et al. NATURE MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now